We propose that treatment of patients with Mn excess with HIF-modulating agents be considered carefully, as our results suggest that HIF2 inhibition, not stabilization, could be beneficial in SLC30A10 deficiency. This evidence concerns the gene SLC30A10 and hyperinsulinemic hypoglycemia, familial, 4.